-
Mashup Score: 4Thrombocytosis - 2 day(s) ago
An asymptomatic 55-year-old woman presented with thrombocytosis discovered 2 years earlier. Laboratory testing revealed the following: hemoglobin 13.1 g/dL, red blood cell count 5.04 × 10 9 /L, hematocrit 41.8%, mean corpuscular volume 83 fL, mean corpuscular hemoglobin concentration 31.3 g/dL, leukocytes 10.87 × 10 9 /L (neutrophils 43%, lymphocytes 45%, monocytes 5%, eosinophils 4%), and platelets 513 × 10 9 /L. Serum ferritin levels were low at 8 ng/mL. Physical examination was unremarkable. Serum
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
Neoantigens arising from recurrent AML mutations are immunogenic and represent novel immunotherapeutic targets.IDH2R140Q-specific T cells can selectively e
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia - 2 day(s) ago
Using 4 illustrative cases, Treon and colleagues discuss their approach to therapy in patients with Waldenström macroglobulinemia (WM) based on genomic pro
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 54
Mutation of thetumor suppressor gene, TP53 (tumor protein 53), occurs in up to 15% of all patients with acute myeloid leukemia (AML) and is enriched within specific clinical subsets, most notably i…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60Kiss of death between CAR‐T cells and KMT2a::AFF1 B lymphoblasts in the central nervous system - 5 day(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 137
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 138Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management - 5 day(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Allogeneic Stem Cell Transplantation for MDS - 5 day(s) ago
Myelodysplastic syndromes are clonal disorders with morphological dysplasia, a variable degree of cytopenia and a risk of transformation to acute myeloid leukemia. Prognosis is very variable and is defined by blast count, cytopenia, cytogenetics and more recently by somatic mutations, with IPSS or revised IPSS score being the most widely used to assess disease risk. HSCT remains the only curative treatment to date, with high-risk patients obtaining the biggest benefit. However, NRM should be carefully assessed before indicating the transplant in this usually old population, where organ toxicity and comorbid conditions are to be considered. Multi-domain assessment tools, such as CGA (comprehensive geriatric assessment) and EBMT score, are useful in this context and might guide physician decisions regarding the transplant. Indeed, with the development of reduced intensity conditioning regimens, the number of patient candidates for an HSCT has increased. Regarding pre-transplant treatment
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 65Pathophysiology of Myelodysplastic Syndromes - 5 day(s) ago
Ineffective hematopoiesis is the major characteristic of early myelodysplastic syndromes. Its pathophysiology relies on a diversity of mechanisms supported by genetic events that develop in aging hematopoietic stem cells. Deletion and mutations trigger epigenetic modifications, and co-transcriptional and post-transcriptional deregulations of gene expression. Epistatic interactions between mutants may aggravate the phenotype. Amplification of minor subclones containing mutations that promote their growth and suppress the others drives the clonal evolution. Aging also participates in reprogramming the immune microenvironment towards an inflammatory state, which precedes the expansion of immunosuppressive cells such as Tregs and myeloid-derived suppressive cells that alters the anti-tumor response of effector cells. Integrating biomarkers of transcription/translation deregulation and immune contexture will help the design of personalized treatments.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
Splenic hypoplasia and thrombocytosis #bloodwork https://t.co/ijfxKcwufc https://t.co/nM9FZKqn5D